Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 30 versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 30 versus VASCORAY.
CONRAY 30 vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent